Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

被引:1
|
作者
Gomez, Ana Marcela Arrieta [1 ]
Diaz-Mendoza, Maria Antonia [2 ]
Lemus, Yesit Bello [1 ]
Leon-Mejia, Grethel [1 ]
Benitez, Martha Lucia Ruiz [1 ]
机构
[1] Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Ctr Invest Ciencias Vida CICV, Cra 53 Calle 64-51, Barranquilla 080002, Colombia
[2] Univ Costa CUC, Dept Comp Sci & Elect, Barranquilla 080002, Colombia
关键词
LMC; Philadelphia chromosome; polymorphism; translocation; resistance; meta-analysis; CHRONIC MYELOGENOUS LEUKEMIA; TROUGH CONCENTRATION; CLINICAL-RESPONSE; PUBLICATION BIAS; MESYLATE; MDR1; MUTATIONS; CYP3A5-ASTERISK-3; SENSITIVITY; PROGENITORS;
D O I
10.3390/scipharm92010002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to establish the relationship between different polymorphisms in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia (CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and PubMed databases using different combinations of keywords with different inclusion and exclusion criteria. The meta-analysis included nine studies that met the established criteria. The results of the study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the SLCO1A2 gene significantly affects the complete molecular response.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] IDENTIFICATION OF POLYMORPHISMS IN GENES RELATED TO THE METABOLISM OF THE DRUGS ASSOCIATED WITH RESISTANCE OR TOXICITY TO IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Natalia, Estrada
    Blanca, Xicoy
    Patricia, Velez
    Laura, Palomo
    Concepcion, Boque
    Iris, De la Fuente
    Miguel, Sagues
    Olga, Garcia
    Marta, Cabezon
    Montserrat, Cortes
    Rolando, Vallansot
    Joan, Buch
    Esther, Plensa
    Dolors, Vela
    Josep-Maria, Ribera
    Evarist, Feliu
    Fuensanta, Milla
    Anna, Sureda
    David, Gallardo
    Josep, Sarra
    Lurdes, Zamora
    HAEMATOLOGICA, 2016, 101 : 179 - 179
  • [2] Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis
    Garcia-Ferrer, Manuel
    Wojnicz, Aneta
    Mejia, Gina
    Koller, Dora
    Zubiaur, Pablo
    Abad-Santos, Francisco
    CLINICAL THERAPEUTICS, 2019, 41 (12) : 2558 - 2570
  • [3] ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
    Zheng, Q.
    Wu, H.
    Yu, Q.
    Kim, D. H.
    Lipton, J. H.
    Angelini, S.
    Soverini, S.
    Vivona, D.
    Takahashi, N.
    Cao, J.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (02): : 127 - 134
  • [4] ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
    Q Zheng
    H Wu
    Q Yu
    D H (Dennis) Kim
    J H Lipton
    S Angelini
    S Soverini
    D Vivona
    N Takahashi
    J Cao
    The Pharmacogenomics Journal, 2015, 15 : 127 - 134
  • [5] POLYMORPHISMS IN ABC TRANSPORTER GENES ARE ASSOCIATED WITH COMPLETE MOLECULAR RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS
    Vivona, D.
    Lima, L.
    Bueno, C.
    Hirata, R.
    Hirata, M.
    Luchessi, A.
    Zanichelli, M.
    Chiattone, C.
    Guerra-Shinohara, E.
    HAEMATOLOGICA, 2012, 97 : 211 - 211
  • [6] Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis
    Gupta, Priyanka
    Banothu, Kiran Kumar
    Haldar, Partha
    Gupta, Aditya Kumar
    Meena, Jagdish Prasad
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (05) : 227 - 234
  • [7] MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
    Louati, N.
    Turki, F.
    Mnif, H.
    Frikha, R.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 39 - 48
  • [8] MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
    Zu, Bailing
    Li, Yajuan
    Wang, Xin
    He, Dali
    Huang, Zhenglan
    Feng, Wenli
    PHARMACOGENOMICS, 2014, 15 (05) : 667 - 677
  • [9] EXPRESSION OF DRUG TRANSPORTER GENES IN CHRONIC MYELOID LEUKEMIA WITH IMATINIB RESISTANCE TREATED BY SECOND GENERATION TYROSINE KINASE INHIBITORS
    Kim, Y.
    Cheong, S.
    Ahn, J.
    Yang, D.
    Lee, J.
    Kim, H.
    HAEMATOLOGICA, 2013, 98 : 555 - 555
  • [10] SINGLE NUCLEOTIDE POLYMORPHISMS IN DRUG-RELATED GENES ARE ASSOCIATED WITH RESISTANCE OR TOXICITY TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA
    Estrada, N.
    Xicoy, B.
    Velez, P.
    Palomo, L.
    Boque, C.
    De la Fuente, I.
    Sagues, M.
    Garcia, O.
    Cabezon, M.
    Cortes, M.
    Vallansot, R.
    Buch, J.
    Plensa, E.
    Vela, D.
    Ribera, J. M.
    Feliu, E.
    Milla, F.
    Sureda, A.
    Gallardo, D.
    Sarra, J.
    Zamora, L.
    HAEMATOLOGICA, 2016, 101 : 450 - 450